Managing comorbidity risks in rheumatoid arthritis

Current Opinion in Rheumatology

Volumn 16, Issue 3, 2004, Pages 177-179

  Dechant, Sonja A ^a   Matteson, Eric L ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIFUNGAL AGENT; ANTIMETABOLITE; ANTIVIRUS AGENT; CHICKENPOX VACCINE; COTRIMOXAZOLE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; DIPHTHERIA TOXOID; FOLIC ACID; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INACTIVATED VACCINE; INFLIXIMAB; INFLUENZA VACCINE; LIVE VACCINE; MEASLES VACCINE; METHOTREXATE; MUMPS VACCINE; NONSTEROID ANTIINFLAMMATORY AGENT; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE; PREDNISONE; PROTON PUMP INHIBITOR; RUBELLA VACCINE; SALAZOSULFAPYRIDINE; TETANUS TOXOID; TOXOID; UNINDEXED DRUG; VALACICLOVIR;

ATHEROSCLEROSIS; CANCER RISK; CARDIOVASCULAR RISK; COMORBIDITY; DISEASE PREDISPOSITION; EDITORIAL; GASTROINTESTINAL SYMPTOM; HOMOCYSTINURIA; HUMAN; HYPERTENSION; INFECTION; INFECTION PREVENTION; INFECTION RISK; KIDNEY DISEASE; LIFESTYLE; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; MORTALITY; OSTEOPOROSIS; PEPTIC ULCER; PNEUMONIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TREATMENT OUTCOME; TREATMENT PLANNING; VACCINATION; VITAMIN SUPPLEMENTATION;

ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; COMORBIDITY; GASTROINTESTINAL DISEASES; HUMANS; INFECTION; NEOPLASMS; OSTEOPOROSIS; RISK;

EID: 1942467800     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200405000-00002     Document Type: Editorial

References (16)

1. Choi HK, Hernan MA, Seeger JD, et al.: Methotrexate and mortality in patients with rheumatoid arthritis. Lancet 2002, 359:1173-1177.
2. Erhardt CC, Mumford PA, Venables PJ, et al.: Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. Ann Rheum Dis 1989, 4:7-13.
3. Gabriel S, Jaakkimainen L, Bombardier C: Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991, 115:787-796.
4. Macfarlane G, Black R: Rheumatoid arthritis and lymphatic cancer. Eur J Cancer 1996, 32:1630-1632.
5. Saag KG: Glucocorticoid-induced osteoporosis. Endocrinol Metabol Clin North Am 2003, 32:135-137. An up-to-date treatment of the pathophysiology and clinical aspects of osteoporosis caused by corticosteroid use.
6. DeMaria AN: Relative risk of cardiovascular events in patients with rheumatoid arthritis. Am J Cardiol 2002, 89:33D-38D.
7. Jean-Frederic Colombel, Loftus EV Jr, Tremaine WJ, et al.: The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004, 126:19-31. A review of experience with infliximab-related side effects including infection, malignancy, and death in a large cohort of patients with Crohn disease treated in open clinical practice.
8. Imperato AK, Smiles S, Abramson SB: Long-term risks associated with biologic response modifiers used in rheumatic diseases. Curr Opinion Rheumatol 2004.
9. Rosandich P, Kelley JT III, Conn DL: Perioperative management of patients with rheumatic arthritis in the era of biologic response modifiers. Curr Opinion Rheumatol 2004.
10. Looney RJ, Anolik J, Sanz I: B cells as therapeutic targets for rheumatic diseases. Curr Opinion Rheumatol 2004.
11. Turesson C, O'Fallon WM, Crowson CS, et al.: Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 2002, 29:62-67.
12. Turesson C, Matteson EL: Management of extra-articular disease manifestations in rheumatoid arthritis. Curr Opinion Rheumatol 2004.
13. Vassalo R: Advances in the treatment of rheumatic interstitial lung disease. Curr Opinion Rheumatol 2004.
14. Doran MF, Crowson CS, Pond GR, et al.: Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002, 46:2294-2300.
15. Stuck AE, Minder CE, Frey FJ: Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989, 11:954-963.
16. Centers for Disease Control and Prevention: Infectious Diseases Society of America, American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR 2000, 49:1-128. Well-referenced guide to preventing and managing infections in immunocompromised hosts, which has practical relevance to patients with rheumatic diseases treated with immunosuppressive drugs.